Penumbra Inc. shares surged by 12.25% as the stock reached a 52-week high following the announcement of its acquisition by Boston Scientific for $374 per share in a cash and stock deal valued at approximately $14.5 billion.
The acquisition allows Boston Scientific to expand into the mechanical thrombectomy and neurovascular markets, addressing the growing demand for vascular disease treatments. The deal is expected to be financed through a combination of cash and new debt, with initial earnings per share dilution anticipated, but a neutral to slightly accretive impact expected in the second year. This strategic move highlights Penumbra's strong market position and innovative product offerings in the healthcare sector.
This acquisition not only enhances Boston Scientific's competitive edge but also underscores Penumbra's significant role in the medical technology landscape, potentially leading to increased investor confidence and market performance.
Wall Street analysts forecast PEN stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for PEN is 344.64 USD with a low forecast of 266.00 USD and a high forecast of 388.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
15 Analyst Rating
Wall Street analysts forecast PEN stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for PEN is 344.64 USD with a low forecast of 266.00 USD and a high forecast of 388.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
14 Buy
1 Hold
0 Sell
Strong Buy
Current: 359.030
Low
266.00
Averages
344.64
High
388.00
Current: 359.030
Low
266.00
Averages
344.64
High
388.00
Truist
Buy
to
Hold
downgrade
$370 -> $374
2026-01-16
Reason
Truist
Price Target
$370 -> $374
AI Analysis
2026-01-16
downgrade
Buy
to
Hold
Reason
Truist downgraded Penumbra to Hold from Buy with a price target of $374, up from $370. The firm cites the recent announcement of its acquisition by Boston Scientific for the downgrade. The deal is highly likely to close without issue, the analyst tells investors in a research note.
Baird
David Rescott
Outperform -> Neutral
downgrade
$345 -> $374
2026-01-16
Reason
Baird
David Rescott
Price Target
$345 -> $374
2026-01-16
downgrade
Outperform -> Neutral
Reason
Baird analyst David Rescott downgraded Penumbra to Neutral from Outperform with a price target of $374, up from $345. The firm cites the pending acquisition by Boston Scientific for the downgrade.
Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for PEN
Unlock Now
Evercore ISI
Vijay Kumar
Outperform
maintain
$286 -> $340
2026-01-05
Reason
Evercore ISI
Vijay Kumar
Price Target
$286 -> $340
2026-01-05
maintain
Outperform
Reason
Evercore ISI analyst Vijay Kumar raised the firm's price target on Penumbra to $340 from $286 and keeps an Outperform rating on the shares. Recovering end markets and sector rotation have "set the stage for a 2026 Tools play," the analyst tells investors. In MedTech, the firm's survey work points to healthy procedure and CapEx trends into 2026 and early recovery signs in China support the group, but sector rotation and potential ACA and Medicare changes "have bears watching," the analyst added.
BofA
Buy
maintain
$320 -> $370
2026-01-05
Reason
BofA
Price Target
$320 -> $370
2026-01-05
maintain
Buy
Reason
BofA raised the firm's price target on Penumbra to $370 from $320 and keeps a Buy rating on the shares as the firm moves the valuation year out one year to reflect the calendar change while highlighting its medtech picks for 2026.
About PEN
Penumbra, Inc. is a thrombectomy company, which is focused on developing technologies for challenging medical conditions, such as ischemic stroke, venous thromboembolism, such as pulmonary embolism, and acute limb ischemia. The Company's broad portfolio, which includes computer assisted vacuum thrombectomy (CAVT), centers on removing blood clots from head-to-toe. It focuses on developing, manufacturing and marketing novel products for use by specialist physicians and healthcare providers to drive improved clinical and health outcomes. Some of the conditions it focuses on are Pulmonary Embolism, Deep Vein Thrombosis, Acute Limb Ischemia, Ischemic Stroke, Acute Coronary Syndrome, and Clot associated with Arteriovenous Graft or Fistula. The Company sells its products to healthcare providers primarily through its direct sales organization in the United States, Europe, Canada and Australia, as well as through distributors in select international markets.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
